PFIZER INC

PFE NYSE CIK: 0000078003

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192
Mailing Address 66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192
Phone 2127332323
Fiscal Year End 1231
EIN 135315170

Financial Overview

FY2025

$8.03B
Net Income
$88.20B
Stockholders' Equity
$1.14B
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 1, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
4 Insider stock transaction report March 30, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
DEF 14A Definitive proxy statement March 12, 2026 View on SEC

Annual Reports

10-K February 26, 2026
  • Strategic pivot to oncology via $43 billion Seagen acquisition, strengthening pipeline and adding over $3 billion revenue in 2024.
  • Achieved approximately 7% operational growth in core biopharma products (excluding COVID-19) despite overall revenue decline.
View Analysis

Material Events

8-K Strategy Change December 16, 2025
High Impact
  • Pfizer updated its financial outlook, narrowing 2025 revenue guidance to approximately $62.0 billion while reaffirming 2025 Adjusted Diluted EPS guidance.
  • New 2026 forecasts project revenues of $59.5 billion to $62.5 billion and Adjusted Diluted EPS of $2.80 to $3.00.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.